W

ith news of Axovant’s big failure in Alzheimer’s, the drug industry is looking ahead to its next major crack at the disease — and it’s a long wait.

In 2019, three large, late-stage Alzheimer’s trials are expected to read out, providing what could be the final word on a trio of drugs that scientists and analysts say represent the next best hope of breaking the industry’s generation of failure in the field.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Biotech newsletter — The Readout

Your daily guide to what’s new in biotech.